{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:58Z","timestamp":1753891258990,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>JAK\/STAT pathway signalling is associated with both chronic inflammatory conditions such as psoriasis and haematological malignancies such as the myeloproliferative neoplasms (MPNs). Here we describe a 73yo female patient with a history of chronic plaque psoriasis, post-essential thrombocythemia myelofibrosis (MF) and a quality of life substantially impacted by both conditions. We report that 15\u2009mg oral Methotrexate (MTX) weekly as a monotherapy is well tolerated, provides a substantial clinical improvement for both conditions and significantly improves quality of life. We suggest that the recently identified mechanism of action of MTX as a JAK inhibitor is likely to explain this efficacy and suggest that repurposing MTX for MPNs may represent a clinical- and cost-effective therapeutic option.<\/jats:p>","DOI":"10.3389\/fmed.2024.1285772","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T04:33:36Z","timestamp":1713414816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: Effectiveness of low-dose methotrexate monotherapy in post-essential thrombocythemia myelofibrosis"],"prefix":"10.3389","volume":"11","author":[{"given":"Sebastian","family":"Francis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin P.","family":"Zeidler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3390\/cancers15041348","article-title":"Deepening our understanding of the factors affecting landscape of myeloproliferative neoplasms: what do we know about them?","volume":"15","author":"Morales","year":"2023","journal-title":"Cancers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/25785826.2022.2139317","article-title":"Recent progress of JAK inhibitors for hematological disorders","volume":"46","author":"Kirito","year":"2022","journal-title":"Immunol Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17512433.2023.2193682","article-title":"JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review","volume":"16","author":"Muddebihal","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.3390\/jcm10194307","article-title":"Role of Janus kinase inhibitors in therapy of psoriasis","volume":"10","author":"Sluczanowska-Glabowska","year":"2021","journal-title":"J Clin Med"},{"volume-title":"Deucravacitinib for treating moderate to severe plaque psoriasis (technology appraisal guidance [TA907])","year":"2023","key":"ref6"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.2174\/092986712803251511","article-title":"Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib","volume":"19","author":"Mascarenhas","year":"2012","journal-title":"Curr Med Chem"},{"volume-title":"Psoriasis: Assessment and management (NICE guideline CG153)","year":"2017","key":"ref9"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3390\/cancers12071954","article-title":"Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature","volume":"12","author":"How","year":"2020","journal-title":"Cancers"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e0130078","DOI":"10.1371\/journal.pone.0130078","article-title":"Methotrexate is a JAK\/STAT pathway inhibitor","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.3324\/haematol.2017.165738","article-title":"Low-dose methotrexate in myeloproliferative neoplasm models","volume":"102","author":"Chinnaiya","year":"2017","journal-title":"Haematologica"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1111\/bjh.16193","article-title":"Low-dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms","volume":"187","author":"Francis","year":"2019","journal-title":"Br J Haematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"E329","DOI":"10.1002\/ajh.24406","article-title":"Low-dose methotrexate as treatment of myeloproliferative neoplasms: proof of principle of clinical activity","volume":"91","author":"Palandri","year":"2016","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1042\/BST20190803","article-title":"How does methotrexate work?","volume":"48","author":"Alqarni","year":"2020","journal-title":"Biochem Soc Trans"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13075-017-1378-x","article-title":"Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy","volume":"19","author":"Teitsma","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"ref18","first-page":"976","article-title":"Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics","volume":"36","author":"Teitsma","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2340\/00015555-2599","article-title":"Methotrexate use and monitoring in patients with psoriasis: a consensus report based on a Danish expert meeting","volume":"97","author":"Raaby","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41408-022-00609-5","article-title":"JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation","volume":"12","author":"Pandey","year":"2022","journal-title":"Blood Cancer J"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1200\/JOP.19.00506","article-title":"Patterns of Ruxolitinib therapy failure and its Management in Myelofibrosis: perspectives of the Canadian myeloproliferative neoplasm group","volume":"16","author":"Gupta","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1285772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T04:33:39Z","timestamp":1713414819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1285772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":23,"alternative-id":["10.3389\/fmed.2024.1285772"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1285772","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"article-number":"1285772"}}